Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'

Phase 2negativeTYK2 pillNegative

AI Analysis

Summary

Alumis' lead TYK2 pill candidate failed a Phase 2 lupus study, representing a clinical setback for the San Francisco biotech. Despite the failure, the CEO indicated the company has identified a clear path forward.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

TYK2 pill failed mid-stage lupus study

Importance:6/10

Sentiment:

-0.80

clinical_setbacklupusTYK2_inhibitormid-stage_trialnegative_data

Read the original article

Published by Endpoints News on September 1, 2026 2:24 PM

Read Original